AbbVie Receives European Commission Approval of ELAHERE® …
1 day ago · "The approval of ELAHERE by the European Commission provides a much needed clinically meaningful option for patients who receive the heartbreaking news their ovarian cancer has returned, fearing ...
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
1 day ago · Elahere generated sales worth $331 million during the first nine months of 2024. The drug is also being studied for earlier lines of therapy in ovarian cancer. Potential label expansion of the ...
AbbVie’s Elahere wins European approval for certain ovarian cancers
1 day ago · GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. As the first FRα-targeted ADC approved in the EU, Elahere represents a competitive ...
AbbVie Receives European Commission Approval of ELAHERE
1 day ago · "The approval of ELAHERE by the European Commission provides a much needed clinically meaningful option for patients who receive the heartbreaking news their ovarian cancer has returned, fearing ...
Mirvetuximab Soravtansine-Gynx Approved for Ovarian Cancer
Apr 24, 2024 · Platinum-resistant ovarian cancer has proven difficult to treat, but with the Food and Drug Administration’s recent full approval of mirvetuximab soravtansine-gynx (Elahere), some people in this situation now have a new treatment option.
AbbVie Completes Acquisition of ImmunoGen - Feb 12, 2024
Feb 12, 2024 · AbbVie Completes Acquisition of ImmunoGen. Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio. ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative ...
U.S. Food and Drug Administration (FDA) Grants Full Approval for ... - News
NORTH CHICAGO, Ill., March 22, 2024 / PRNewswire / -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for ELAHERE® (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary ...
FDA approves mirvetuximab soravtansine-gynx (Elahere, …
On March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult patients with FRα positive,...
AbbVie to Acquire ImmunoGen, including its Flagship Cancer ... - News
Nov 30, 2023 · ELAHERE ® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer; ImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populations
FDA grants accelerated approval to mirvetuximab soravtansine …
On November 14, 2022, the Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc.) for adult patients with folate receptor alpha...
- Some results have been removed